Mark Febbraio

Professor Mark Febbraio is a Principal Research Fellow of the NHMRC, head of the Cellular and Molecular Metabolism Laboratory and Director of Basic Science in the Division of Metabolism and Obesity at Baker IDI Heart and Diabetes Institute. He currently oversees approximately 40 staff and students. His laboratory is focussed on understanding cellular and molecular mechanisms associated with lipid-induced inflammation and insulin resistance. While his career has been exclusively in academia, having authored over 130 peer reviewed papers in leading journals such as Nature Medicine, The Journal of Clinical Investigation, PNAS and Diabetes, he has an immerging track record in product pipeline research. Most notably, he discovered that the HSP72 activator BGP-15 can ameliorate insulin resistance in mice. This has led to him being appointed Chief Scientific Officer of the company N-Gene Pharmaceuticals. The company now has BGP-15 in a late stage clinical trial. Dr Febbraio has also patented IC7. Finally, he is also in the Scientific board of another International company, Vitagenes Inc.

TECHNOLOGIES

New treatment for glucose and weight control

SECTORS

CATEGORIES

Cardiovascular disease

Diabetes

Diagnostics

Medical

Medical Devices

Personalised Healthcare

Target

Therapeutic

Tool